Needham Reiterates Buy on Rhythm Pharmaceuticals, Maintains $32 Price Target
Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $32 price target.
Related Posts
Wells Fargo Press Release Confirms Its New Digital Infrastructure Strategy Will Include Partnerships With Microsoft, Google CLoud
Wells Fargo & Company (NYSE:WFC) announced today its new digital infrastructure strategy, combining a multi-cloud approach with third-party data centers to drive technological speed, agility, and scalability for its
Dali Wireless and Corning Resolved Patent Disputes
Dali Wireless, Inc. ("Dali"), a worldwide pioneer in digital radio distribution systems and digital pre-distortion technology, today announced that it has settled its numerous patent disputes with Corning Inc. and Corning Optical Communications LLC, which is a wholly-owned subsidiary of Corning Incorporated (together "Corning").
Tilray Stock Soars Then Returns To Earth On Biden’s Cannabis Pardon News, This Analyst Remains Neutral
On the heels of President Biden’s historic announcement that he was pardoning all federal marijuana possession convictions, Cantor Fitzgerald's